371 related articles for article (PubMed ID: 22326484)
21. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data.
Stern L; Berman J; Lumry W; Katz L; Wang L; Rosenblatt L; Doyle JJ
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):402-8. PubMed ID: 17042149
[TBL] [Abstract][Full Text] [Related]
22. Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
Hagiwara M; Delea TE; Stanford RH
J Asthma; 2011 Sep; 48(7):721-8. PubMed ID: 21793768
[TBL] [Abstract][Full Text] [Related]
23. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities.
O'Connor RD; Parasuraman B; Roberts C; Leibman C
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):236-43. PubMed ID: 16937758
[TBL] [Abstract][Full Text] [Related]
24. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
Orsini L; Limpa-Amara S; Crown WH; Stanford RH; Kamal K
Ann Allergy Asthma Immunol; 2004 May; 92(5):523-9. PubMed ID: 15191020
[TBL] [Abstract][Full Text] [Related]
25. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study.
Dal Negro RW; Micheletto C; Tosatto R; Dionisi M; Turco P; Donner CF
Respir Med; 2007 Dec; 101(12):2511-9. PubMed ID: 17822890
[TBL] [Abstract][Full Text] [Related]
26. [Rate and characteristics of asthma exacerbations: the ASMAB I study].
Morell F; Genover T; Muñoz X; García-Aymerich J; Ferrer J; Cruz MJ
Arch Bronconeumol; 2008 Jun; 44(6):303-11. PubMed ID: 18559219
[TBL] [Abstract][Full Text] [Related]
27. An employer perspective on annual employee and dependent costs for pediatric asthma.
Kleinman NL; Brook RA; Ramachandran S
Ann Allergy Asthma Immunol; 2009 Aug; 103(2):114-20. PubMed ID: 19739423
[TBL] [Abstract][Full Text] [Related]
28. Initiation of maintenance antiinflammatory medication in asthmatic children in a pediatric emergency department.
Lehman HK; Lillis KA; Shaha SH; Augustine M; Ballow M
Pediatrics; 2006 Dec; 118(6):2394-401. PubMed ID: 17142524
[TBL] [Abstract][Full Text] [Related]
29. Resource costs for asthma-related care among pediatric patients in managed care.
Gendo K; Sullivan SD; Lozano P; Finkelstein JA; Fuhlbrigge A; Weiss KB
Ann Allergy Asthma Immunol; 2003 Sep; 91(3):251-7. PubMed ID: 14533656
[TBL] [Abstract][Full Text] [Related]
30. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
31. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
[TBL] [Abstract][Full Text] [Related]
32. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
33. Economic burden of rhinitis in managed care: a retrospective claims data analysis.
Dalal AA; Stanford R; Henry H; Borah B
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):23-9. PubMed ID: 18681080
[TBL] [Abstract][Full Text] [Related]
34. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
[TBL] [Abstract][Full Text] [Related]
35. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database.
Schatz M; Zeiger RS; Yang SJ; Chen W; Crawford WW; Sajjan SG; Allen-Ramey F
Am J Manag Care; 2010 May; 16(5):327-33. PubMed ID: 20469953
[TBL] [Abstract][Full Text] [Related]
36. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
37. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
38. Correlation of care process measures with childhood asthma exacerbations.
Vernacchio L; Trudell EK; Muto JM
Pediatrics; 2013 Jan; 131(1):e136-43. PubMed ID: 23209109
[TBL] [Abstract][Full Text] [Related]
39. Economic burden of impairment in children with severe or difficult-to-treat asthma.
Szefler SJ; Zeiger RS; Haselkorn T; Mink DR; Kamath TV; Fish JE; Chipps BE
Ann Allergy Asthma Immunol; 2011 Aug; 107(2):110-119.e1. PubMed ID: 21802018
[TBL] [Abstract][Full Text] [Related]
40. Impact of a targeted asthma intervention program on treatment costs in patients with asthma.
Suh DC; Shin SK; Okpara I; Voytovich RM; Zimmerman A
Am J Manag Care; 2001 Sep; 7(9):897-906. PubMed ID: 11570023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
